Diplomat Pharmacy Inc

Diplomat Pharmacy — Q2 2018 Earnings Presentation

16 slides from Diplomat Pharmacy's earnings presentation, Aug 6, 2018

  1. Slide 1: Disclaimers: Non-GAAP Information

    Disclaimers 2 NON-GAAP INFORMATION Adjusted non-GAAP net income and Adjusted EPS add back, net of income taxes, the impact of all merger and acquisition related expenses, including amortization of intangible assets, the change in fair value of contingent consideration, as well as transaction-related

  2. Slide 2: Opening Remarks

    Opening Remarks Brian Griffin, Chairman & CEO

  3. Slide 3: 2Q 2018 Highlights

    1 A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net (loss) income attributable to Diplomat, as prepared in accordance with GAAP can be found in the Appendix to this presentation. 2Q 2018 Highlights $1.4B (+26%) Revenue $43M (+70%) Adjusted EBITDA1 4 Solid growth in specialty and infusi

  4. Slide 4: CastiaRx Highlights 2Q 2018

    CastiaRx Highlights 5 2Q 2018 Integration almost complete $3M in 2Q synergies achieved, YTD total of $4M Now expect $8M-$10M in synergies in 2018 (vs. prior expectation of $4M-$6M) Process begun to move legacy PBM patients on LDDs to Diplomat specialty pharmacy Proposal volume remains double a year

  5. Slide 5: Putting Patients First

    Putting Patients First 6 Specialty Pharmacy Solutions PBM Manufacturer Services Infrastructure Innovation Infusion Employees The industry’s largest independent provider of specialty pharmacy services Specialty-focused PBM targeting middle market clients Nationwide provider of infusion management ser

  6. Slide 6: Financial Results

    Financial Results Atul Kavthekar, CFO

  7. Slide 7: 2Q 2018 Financial Results

    ($0.05) ($4.0M) A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net (loss) income attributable to Diplomat as prepared in accordance with GAAP, can be found in the Appendix to this presentation. A reconciliation of Adjusted non-GAAP net income and Adjusted EPS, both non-GAAP measures, to

  8. Slide 8: 2Q 2018 Segment Details

    2Q 2018 Segment Details 9 Specialty PBM Revenue: $1.2B Gross margin1: 5.9% Rx volume: 236,000 Net Sales / Rx: $5,218 Gross profit / Rx1: $301 Revenue: $0.2B Gross margin: 13.7% Rx volume2: 2,123,000 Gross profit / Rx: $12 Beginning with the second quarter of 2018, certain direct expenses have been r

  9. Slide 9: Specialty Segment Cost of Sales Reclassification

    Specialty Segment Cost of Sales Reclassification In the Specialty segment, certain direct expenses (shipping & handling costs and nursing costs), that were previously classified in SG&A, are now presented in cost of sales. Changes are only a reclassification and do not impact Adjusted EBITDA, Income

  10. Slide 10: Revised 2018 Full Year Outlook

    Revised 2018 Full Year Outlook Investing for long-term growth and operational efficiency Stable margins with potential upside Deleveraging to 2-3x adjusted EBITDA in 2019 TOTAL REVENUE $5.5B - $5.9B TOTAL ADJUSTED EBITDA1 $164M - $170M 11 GAAP EPS ($0.15) - $0.01 CASH FLOW FROM OPERATIONS $115M - $1

  11. Slide 11: Putting Patients First

    Putting Patients First 12 Specialty Pharmacy Solutions PBM Manufacturer Services Infrastructure Innovation Infusion Employees JAY DIPLOMAT PATIENT

  12. Slide 12: Appendix: Supplemental Financial Information

    Appendix Supplemental Financial Information

  13. Slide 13: Reconciliation of Net (Loss) Income to Adjusted EBITDA

    Reconciliation of Net (Loss) Income Attributable to Diplomat to Adjusted EBITDA 14

  14. Slide 14: Reconciliation of Net (Loss) Income Per Diluted Share to Adjusted EPS

    Reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the periods indicated. Please note that this will be the last time this table is provided. Going forward, Diplomat will no longer present, or provide guidance with respect to Adjusted no

  15. Slide 15: 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation

    2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation Assumes a tax rate of (5) and 32 percent, for the low- and high-end, respectively. 16 The tables below present a reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA for the year ended December 31, 201

  16. Slide 16: 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation

    DIPLOMATA 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation ‘The tables below present a reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA forthe year ended December 31,2018 Reconciliation of 2018 GAAP to Adjusted EBITDA Guidance (olars in thousands

Diplomat Pharmacy — Q2 2018 Earnings Presentation on 6ix